202 related articles for article (PubMed ID: 34742684)
21. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
22. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
23. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
24. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.
McDermott U; Pusapati RV; Christensen JG; Gray NS; Settleman J
Cancer Res; 2010 Feb; 70(4):1625-34. PubMed ID: 20124471
[TBL] [Abstract][Full Text] [Related]
25. [Research Progress of the Role of EMT in EGFR-TKIs Resistance
of Non-small Cell Lung Cancer].
Yu L; Huang S; Lv W; He Z; Hu J
Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):907-911. PubMed ID: 30591098
[TBL] [Abstract][Full Text] [Related]
26. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
27. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
28. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
29. [Current management and future prospect of HER-2 mutant non-small cell lung cancer].
Xu F; Wang Y
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):829-837. PubMed ID: 33113623
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
31. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
[TBL] [Abstract][Full Text] [Related]
32. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
34. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy.
Gazdar AF
Cancer Metastasis Rev; 2010 Mar; 29(1):37-48. PubMed ID: 20127143
[TBL] [Abstract][Full Text] [Related]
36. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
37. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
[TBL] [Abstract][Full Text] [Related]
38. Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
Prabhu VV; Devaraj N
J Environ Pathol Toxicol Oncol; 2017; 36(2):151-158. PubMed ID: 29199595
[TBL] [Abstract][Full Text] [Related]
39. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
40. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.
Nishino M; Dahlberg SE; Cardarella S; Jackman DM; Rabin MS; Ramaiya NH; Hatabu H; Jänne PA; Johnson BE
Cancer; 2013 Nov; 119(21):3761-8. PubMed ID: 23922022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]